Invesco Ltd. raised its stake in shares of Kadmon Holdings Inc (NYSE:KDMN) by 2.2% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,823,033 shares of the company’s stock after buying an additional 39,255 shares during the quarter. Invesco Ltd.’s holdings in Kadmon were worth $3,755,000 at the end of the most recent reporting period.
Several other institutional investors also recently bought and sold shares of KDMN. Vanguard Group Inc. lifted its holdings in shares of Kadmon by 5.9% during the 2nd quarter. Vanguard Group Inc. now owns 5,713,561 shares of the company’s stock valued at $11,770,000 after purchasing an additional 320,710 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of Kadmon by 23.5% during the 2nd quarter. BlackRock Inc. now owns 8,428,750 shares of the company’s stock valued at $17,363,000 after purchasing an additional 1,605,568 shares in the last quarter. Parametric Portfolio Associates LLC bought a new position in shares of Kadmon during the 2nd quarter valued at about $30,000. Sofinnova Investments Inc. lifted its holdings in shares of Kadmon by 31.8% during the 2nd quarter. Sofinnova Investments Inc. now owns 2,204,202 shares of the company’s stock valued at $4,540,000 after purchasing an additional 532,432 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in shares of Kadmon by 9.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 407,211 shares of the company’s stock valued at $839,000 after purchasing an additional 34,555 shares in the last quarter. Institutional investors own 77.02% of the company’s stock.
Several equities analysts have recently weighed in on KDMN shares. Oppenheimer started coverage on Kadmon in a report on Wednesday, June 26th. They set an “outperform” rating and a $6.00 price objective on the stock. Zacks Investment Research upgraded Kadmon from a “hold” rating to a “buy” rating and set a $3.00 price objective on the stock in a report on Wednesday, October 9th. Cantor Fitzgerald began coverage on Kadmon in a report on Thursday, September 5th. They set an “overweight” rating and a $8.00 price objective on the stock. Finally, ValuEngine cut Kadmon from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Kadmon currently has a consensus rating of “Buy” and an average target price of $7.95.
Kadmon (NYSE:KDMN) last released its earnings results on Monday, August 5th. The company reported ($0.19) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by ($0.03). The firm had revenue of $0.23 million during the quarter, compared to the consensus estimate of $0.46 million. Kadmon had a negative net margin of 3,974.23% and a negative return on equity of 96.96%. As a group, equities analysts anticipate that Kadmon Holdings Inc will post -0.54 earnings per share for the current fiscal year.
Kadmon Company Profile
Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes products in various therapeutic areas, including ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease.
See Also: What is Cost of Debt?
Want to see what other hedge funds are holding KDMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kadmon Holdings Inc (NYSE:KDMN).
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.